NAD replenishment with nicotinamide mononucleotide protects blood–brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia

British Journal of Pharmacology

Volumn 174, Issue 21, 2017, Pages 3823-3836

  Wei, Chun Chun ^a   Kong, Yuan Yuan ^a   Hua, Xia ^a   Li, Guo Qiang ^a   Zheng, Si Li ^a   Cheng, Ming He ^a   Wang, Pei ^a,b   Miao, Chao Yu ^a,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b YANTAI UNIVERSITY   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 1; GELATINASE A; GELATINASE B; HEMOGLOBIN; MATRIX METALLOPROTEINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE NUCLEOTIDE; OCCLUDIN; PROTEIN ZO1; TIGHT JUNCTION PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CELL ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG STRUCTURE; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; REPERFUSION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECT; METABOLISM; PATHOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; INTRACRANIAL HEMORRHAGES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; NAD; NICOTINAMIDE MONONUCLEOTIDE; TIGHT JUNCTION PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 85028929088     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13979     Document Type: Article

References (60)

1. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
2. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 172: 5729–5743.
3. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
4. Dagon Y, Mantzoros CS, Kim YB (2016). AMPK<–>Sirt1: from a signaling network to a combination drug. Metabolism: clinical and experimental 65: 1692–1694.
5. de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sindler AL, Mills KF et al. (2016). Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell 15: 522–530.
6. Docagne F, Parcq J, Lijnen R, Ali C, Vivien D (2015). Understanding the functions of endogenous and exogenous tissue-type plasminogen activator during stroke. Stroke; a journal of cerebral circulation 46: 314–320.
7. Garcia-Culebras A, Palma-Tortosa S, Moraga A, Garcia-Yebenes I, Duran-Laforet V, Cuartero MI et al. (2017). Toll-like receptor 4 mediates hemorrhagic transformation after delayed tissue plasminogen activator administration in in situ thromboembolic stroke. Stroke; a journal of cerebral circulation 48: 1695–1699.
8. Garten A, Schuster S, Penke M, Gorski T, de Giorgis T, Kiess W (2015). Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol 11: 535–546.
9. Hafez S, Abdelsaid M, El-Shafey S, Johnson MH, Fagan SC, Ergul A (2016). Matrix metalloprotease 3 exacerbates hemorrhagic transformation and worsens functional outcomes in hyperglycemic stroke. Stroke 47: 843–851.
10. Imai S, Guarente L (2014). NAD+ and sirtuins in aging and disease. Trends Cell Biol 24: 464–471.
11. Jokinen R, Pirnes-Karhu S, Pietilainen KH, Pirinen E (2017). Adipose tissue NAD+−homeostasis, sirtuins and poly(ADP-ribose) polymerases – important players in mitochondrial metabolism and metabolic health. Redox Biol 12: 246–263.
12. Kanazawa M, Igarashi H, Kawamura K, Takahashi T, Kakita A, Takahashi H et al. (2011). Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment. J Cereb Blood Flow Metab 31: 1461–1474.
13. Kastrup A, Groschel K, Ringer TM, Redecker C, Cordesmeyer R, Witte OW et al. (2008). Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. Stroke; a journal of cerebral circulation 39: 2385–2387.
14. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
15. Larrue V, von Kummer RR, Muller A, Bluhmki E (2001). Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke; a journal of cerebral circulation 32: 438–441.
16. Li DJ, Li YH, Yuan HB, Qu LF, Wang P (2017). The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism: clinical and experimental 68: 31–42.
17. Liang J, Qi Z, Liu W, Wang P, Shi W, Dong W et al. (2015). Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia. Stroke 46: 1344–1351.
18. Liu H, Wang Y, Xiao Y, Hua Z, Cheng J, Jia J (2016). Hydrogen sulfide attenuates tissue plasminogen activator-induced cerebral hemorrhage following experimental stroke. Translational stroke research 7: 209–219.
19. Long AN, Owens K, Schlappal AE, Kristian T, Fishman PS, Schuh RA (2015). Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer's disease-relevant murine model. BMC Neurol 15: 19.
20. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One 7 e42357.
21. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
22. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH (2008). Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke; A Journal of Cerebral Circulation 39: 3372–3377.
23. Park JH, Long A, Owens K, Kristian T (2016). Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia. Neurobiol Dis 95: 102–110.
24. Porter AG, Janicke RU (1999). Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99–104.
25. Rempe RG, Hartz AM, Bauer B (2016). Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab 36: 1481–1507.
26. Rich PR (2003). The molecular machinery of Keilin's respiratory chain. Biochem Soc Trans 31: 1095–1105.
27. Rom S, Zuluaga-Ramirez V, Dykstra H, Reichenbach NL, Ramirez SH, Persidsky Y (2015). Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions. J Cereb Blood Flow Metab 35: 28–36.
28. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054–D1068.
29. Stein LR, Imai S (2014). Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. EMBO J 33: 1321–1340.
30. Uddin GM, Youngson NA, Sinclair DA, Morris MJ (2016). Head to head comparison of short-term treatment with the NAD(+) precursor nicotinamide mononucleotide (NMN) and 6 weeks of exercise in obese female mice. Front Pharmacol 7: 258.
31. Wang L, Fan W, Cai P, Fan M, Zhu X, Dai Y et al. (2013). Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice. Ann Neurol 73: 189–198.
32. Wang P, Du H, Zhou CC, Song J, Liu X, Cao X et al. (2014a). Intracellular NAMPT-NAD+−SIRT1 cascade improves post-ischaemic vascular repair by modulating Notch signalling in endothelial progenitors. Cardiovasc Res 104: 477–488.
33. Wang P, Guan YF, Du H, Zhai QW, Su DF, Miao CY (2012). Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy 8: 77–87.
34. Wang P, Guan YF, Li WL, Lu GC, Liu JM, Miao CY (2015). Nicotinamide phosphoribosyltransferase facilitates post-stroke angiogenesis. CNS Neurosci Ther 21: 475–477.
35. Wang P, Miao CY (2015). NAMPT as a therapeutic target against stroke. Trends Pharmacol Sci 36: 891–905.
36. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY (2009). Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 81: 370–380.
37. Wang P, Xu TY, Guan YF, Tian WW, Viollet B, Rui YC et al. (2011). Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol 69: 360–374.
38. Wang P, Xu TY, Guan YF, Zhao Y, Li ZY, Lan XH et al. (2014b). Vascular smooth muscle cell apoptosis is an early trigger for hypothyroid atherosclerosis. Cardiovasc Res 102: 448–459.
39. Wang P, Xu TY, Wei K, Guan YF, Wang X, Xu H et al. (2014c). ARRB1/beta-arrestin-1 mediates neuroprotection through coordination of BECN1-dependent autophagy in cerebral ischemia. Autophagy 10: 1535–1548.
40. Wang P, Yang X, Zhang Z, Song J, Guan YF, Zou DJ et al. (2016a). Depletion of NAD pool contributes to impairment of endothelial progenitor cell mobilization in diabetes. Metabolism: clinical and experimental 65: 852–862.
41. Wang SN, Xu TY, Wang X, Guan YF, Zhang SL, Wang P et al. (2016b). Neuroprotective efficacy of an aminopropyl carbazole derivative P7C3-A20 in ischemic stroke. CNS Neurosci Ther 22: 782–788.
42. Wang X, Asahi M, Lo EH (1999). Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures. Neurosci Lett 274: 79–82.
43. Wang X, Mori T, Sumii T, Lo EH (2002). Hemoglobin-induced cytotoxicity in rat cerebral cortical neurons: caspase activation and oxidative stress. Stroke; a journal of cerebral circulation 33: 1882–1888.
44. Wei CC, Kong YY, Li GQ, Guan YF, Wang P, Miao CY (2017). Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci Rep 7: 717.
45. Won S, Lee JK, Stein DG (2015). Recombinant tissue plasminogen activator promotes, and progesterone attenuates, microglia/macrophage M1 polarization and recruitment of microglia after MCAO stroke in rats. Brain Behav Immun 49: 267–279.
46. Yang F, Zhou L, Wang D, Wang Z, Huang QY (2015). Minocycline ameliorates hypoxia-induced blood-brain barrier damage by inhibition of HIF-1alpha through SIRT-3/PHD-2 degradation pathway. Neuroscience 304: 250–259.
47. Yang J, Klaidman LK, Nalbandian A, Oliver J, Chang ML, Chan PH et al. (2002). The effects of nicotinamide on energy metabolism following transient focal cerebral ischemia in Wistar rats. Neurosci Lett 333: 91–94.
48. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA (2007). Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27: 697–709.
49. Yang Y, Rosenberg GA (2011). Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke; a journal of cerebral circulation 42: 3323–3328.
50. Yoshino J, Mills KF, Yoon MJ, Imai S (2011). Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 14: 528–536.
51. Zhang DX, Zhang JP, Hu JY, Huang YS (2016). The potential regulatory roles of NAD(+) and its metabolism in autophagy. Metabolism: clinical and experimental 65: 454–462.
52. Zhang L, Chopp M, Jia L, Cui Y, Lu M, Zhang ZG (2009). Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab 29: 1816–1824.
53. Zhang L, Zhang RL, Jiang Q, Ding G, Chopp M, Zhang ZG (2015). Focal embolic cerebral ischemia in the rat. Nat Protoc 10: 539–547.
54. Zhang RY, Qin Y, Lv XQ, Wang P, Xu TY, Zhang L et al. (2011). A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase. Anal Biochem 412: 18–25.
55. Zhao L, An R, Yang Y, Yang X, Liu H, Yue L et al. (2015a). Melatonin alleviates brain injury in mice subjected to cecal ligation and puncture via attenuating inflammation, apoptosis, and oxidative stress: the role of SIRT1 signaling. J Pineal Res 59: 230–239.
56. Zhao Y, Guan YF, Zhou XM, Li GQ, Li ZY, Zhou CC et al. (2015b). Regenerative neurogenesis after ischemic stroke promoted by nicotinamide phosphoribosyltransferase-nicotinamide adenine dinucleotide cascade. Stroke 46: 1966–1974.
57. Zhao Y, Liu XZ, Tian WW, Guan YF, Wang P, Miao CY (2014). Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury. CNS Neurosci Ther 20: 539–547.
58. Zhou CC, Yang X, Hua X, Liu J, Fan MB, Li GQ et al. (2016). Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol 173: 2352–2368.
59. Zhou XM, Zhang X, Zhang XS, Zhuang Z, Li W, Sun Q et al. (2014). SIRT1 inhibition by sirtinol aggravates brain edema after experimental subarachnoid hemorrhage. J Neurosci Res 92: 714–722.
60. Zuo W, Chen J, Zhang S, Tang J, Liu H, Zhang D et al. (2014). IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation. Eur J Neurosci 39: 2107–2118.